JPRN-UMIN000005329已完成2 期
A randomized clinical trial of personalized peptide vaccination with oral low-dose metronomic cyclophosphamide for metastatic castration-resistant prostate cancer (CRPC) - Personalized peptide vaccination with metronomic cyclophosphamide for metastatic CRPC
Kurume University School of medicine, Department of Immunology and immunotherapy0 个研究点目标入组 60 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Patients who are judged inappropriate for the clinical trial by doctors.
研究者
相似试验
已完成
2 期
A randomised phase II trial of personalized peptide vaccination plus "Keppuchikuoto" vs personalized peptide vaccination alone for non small cell lung cancer patientsnresectable non smaii cell lung cancerJPRN-UMIN000015173Kurume Unversity Cancer Vaccine Center60
已完成
2 期
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000019879Cancer Vaccine Center, Kurume University School of medicine35
已完成
2 期
A phase 2 clinical trial of personalized peptide vaccination for castration-resistant prostate cancer (CRPC) patients with slight bone marrow suppressioJPRN-UMIN000019802Cancer Vaccine Center, Kurume University School of medicine35
已完成
2 期
A phase two clinical trial of the personalized peptide vaccine for the recurrence prevention in pediatric cancer patientsPediatric cancer patientsJPRN-UMIN000030249Kurume University Cancer Vaccine Center50
已完成
2 期
A phase two clinical trial of the personalized peptide vaccine for standard therapy-resistant pediatric cancer patientsThe pediatric patients who are resistant for standard therapy.JPRN-UMIN000023422Kurume University Cancer Vaccine Center50